Issue of equity in respect of exercise of options

RNS Number : 5040L

Allergy Therapeutics PLC

03 October 2016

 



3 October 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Issue of equity in respect of the exercise of options

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the issue and allotment of 3,441,000 new ordinary shares of 0.1p each in the capital of the Company ("Ordinary Shares") pursuant to the exercise of 3,441,000 share options by certain employees. Of this number of share options, an amount of the share options have been exercised by persons discharging management responsibility ("PDMRs").

At the same time, the Company has received notice from certain PDMRs that they have immediately sold Ordinary Shares in respect of the share options exercised.

The exercise of share options and the sale of Ordinary Shares by the respective PDMRs are detailed below:

PDMR	Ordinary Shares received upon exercise of share options	Ordinary Shares sold	Price per Ordinary share sold	Resulting beneficial holding of Ordinary Shares	Resulting percentage of voting rights in the Company at Admission
Sue Baker	160,000	160,000	19.0p	27,900	0.01%
Alastair Friend	80,000	80,000	19.5p	-	-
Nunzio Di Grazia	452,500	452,500	19.5p	-	-
Bev Lees	160,000	160,000	19.5p	-	-
Russell Pickett	160,000	160,000	19.5p	-	-
Santiago Puig	452,500	452,500	19.5p	-	-
Murray Skinner	160,000	160,000	19.5p	-	-
Bodo Steinert	452,500	226,250	19.5p	388,262	0.07%

Application has been made to the London Stock Exchange for admission to trading of the 3,441,000 new Ordinary Shares on AIM ("Admission") in respect of the exercise of the share options. It is expected that Admission will take place and that dealings in the new Ordinary Shares on AIM will commence at 8:00 a.m. on 6 October 2016, at which time the sale of Ordinary Shares will occur. The new Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares in the capital of the Company, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after the date of issue of the new Ordinary Shares.

Allergy Therapeutics' enlarged issued ordinary share capital immediately following Admission will be 593,364,020 Ordinary Shares with voting rights attached. The Company has no Ordinary Shares in Treasury; therefore, the total number of voting rights in Allergy Therapeutics is 593,364,020. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

[phone]

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

[e-mail]

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

 

END

 

 

DSHEAEEDEAKKFFF